Kyowa kirin pays $100m upfront to bridgebio for skeletal dysplasias drug in japan – Artofit

Image gallery for: Kyowa kirin pays $100m upfront to bridgebio for skeletal dysplasias drug in japan

Kyowa Kirin Pays $100M Upfront to BridgeBio for Skeletal Dysplasias Drug in Japan

Kyowa Kirin’s dealmaking continued on Wednesday when BridgeBio Pharma granted the Japanese company an exclusive license to develop and commercialize infigratinib.
Advertisement
The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture

Michael Deem
What is it like to attend a predatory conference?

Reading things
With 70% Efficacy, AstraZeneca-Oxford COVID-19 Vaccine Heads to Regulators

A Covid Pandemic
Embryo model made using pluripotent stem cells reveals details of early development in humans

bioinspired design 🌸
Advertisement
How much would you pay for free shipping?

Michael Deem
AI is vulnerable to attack. Can it ever be used safely?

Michael Deem
How I create virtual twins for fabrics and furniture

Michael Deem
Transcranial volumetric imaging using a conformal ultrasound patch

Michael Deem
Five ways the brain can age: 50,000 scans reveal possible patterns of damage

Brain & Migraines
Peter Higgs obituary: physicist who predicted boson that explains why particles have mass

Michael Deem
Phononic switching of magnetization by the ultrafast Barnett effect

Michael Deem
Advertisement
Advertisement
Advertisement
Coupled neural activity controls working memory in humans

bioinspired design 🌸